[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-373353-105":59,"doc-detail-373353-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","advancements-in-cell-membrane-derived-biomimetic-nanotherapeutics-for-breast-cancer-review","Advancements in Cell Membrane-Derived Biomimetic Nanotherapeutics for Breast Cancer - review","","Breast cancer remains a major cause of female mortality worldwide, requiring advanced strategies for its heterogeneous subtypes. Nanotechnology is increasingly used because nanoscale carriers offer multiple tunable properties, controlled drug administration, and potential synergistic therapeutic effects. Yet immune recognition and clearance often reduce efficacy, limiting performance of conventional nanoparticles. Cell membrane-based delivery systems provide biocompatible, targeting-specific alternatives derived from blood cells, cancer cells, and stem cells, improving circulation and tumor biomarker recognition, and supporting diagnostic, photothermal therapy, and vaccine development.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancements-in-cell-membrane-derived-biomimetic-nanotherapeutics-for-breast-cancer-review/373353/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancements-in-cell-membrane-derived-biomimetic-nanotherapeutics-for-breast-cancer-review/373353.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are nanotechnology-based carriers considered for breast cancer therapy?","Question",{"text":113,"@type":114},"They operate at the nanoscale, support diverse carrier designs, enable hydrophobic drug delivery, and allow controlled and targeted administration. Nanoparticles can be engineered for active or passive targeting and may provide synergistic effects.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What limits the effectiveness of many conventional nanoparticles in breast cancer?",{"text":118,"@type":114},"The immune system can detect and remove nanoparticles from the body, which restricts circulation time and reduces therapeutic efficacy.",{"name":120,"@type":111,"acceptedAnswer":121},"How do cell membrane-derived nanoparticle systems improve tumor targeting?",{"text":122,"@type":114},"Cell membranes disguise nanoparticles in the bloodstream, enhance retention time in vivo, and leverage membrane-derived targeting properties to recognize breast cancer tumors and associated biomarkers. This approach has been explored for diagnostics, photothermal therapy, and vaccine development.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},373353,1790371650,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","International Journal of Nanomedicine  \nOpen Access Full Text Article REVIEW  \nAdvancements in Cell Membrane-Derived Biomimetic Nanotherapeutics for Breast Cancer  \nMingtang Zeng 1 , 2 , *, Chenji Hu 1 , *, Tao Chen 3 , Tingrui Zhao4 , Xinhua Dai2  \n1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China; 2Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China; 3Pharmacy Department, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing, 400014, People’s Republic of China; 4Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, 621000, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Tingrui Zhao, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, 621000, People’s Republic of China, Email [tingruizhao0801@163.com](tingruizhao0801@163.com); Xinhua Dai, Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China, Email [dxh9123@163.com](dxh9123@163.com)  \n\n| Abstract: Breast cancer remains the leading cause of female mortality worldwide, necessitating innovative and multifaceted approaches to address its various subtypes. Nanotechnology has attracted considerable attention due to its nanoscale dimensions, diverse carrier types, suitability for hydrophobic drug delivery, and capacity for controlled and targeted administration. Nano-sized particles have become prevalent carriers for therapeutic agents targeting breast cancer, thanks to their reproducible synthesis and adjustable properties, including size, shape, and surface characteristics. In addition, certain nanoparticles can enhance therapeutic effects synergistically. However, the immune system often detects and removes these nanoparticles, limiting their efficacy. Asa promising alternative, cell membrane-based delivery systems have gained attention due to their biocompatibility and targeting specificity. These membrane-coated drug delivery systems are derived from various cell sources, including blood cells, cancer cells, and stem cells. Leveraging the unique properties of these cell membranes enables precise targeting of breast cancer tumors and associated biomarkers. Inspired by natural structures, cell membranes disguise nanoparticles in the bloodstream, enhancing their retention time in vivo and improving tumor targeting. Consequently, cell membrane-derived nanoparticles (CMDNPs) have been investigated for their potential applications in breast cancer diagnostics, photothermal therapy (PTT), and vaccine development. This review comprehensively explores the potential and limitations of cell membrane-derived drug delivery systems in clinical applications against breast cancer.\u003Cbr>Keywords: cell membrane-derived nanoparticles, breast cancer, active targeting, combination therapy, biomimetic delivery systems |\n| --- |\n| Introduction\u003Cbr>Breast cancer remains one of the most prevalent and deadly malignancies affecting women worldwide. According to recent statistics, over 2.3 million new cases of breast cancer were diagnosed globally in 2022, and it accounted for approximately 665,000 deaths.1 This makes breast cancer not only the most commonly diagnosed cancer in women but also a significant public health challenge. Despite advances in early detection and treatment, the mortality rate remains high due to the complex nature of the disease and the limitations of current therapeutic strategies.2 Traditional breast cancer treatments such as surgery, chemotherapy, and radiotherapy have been the cornerstone of clinical management for decades.3–5 However, these treatments are often associated with several drawbacks, including limited efficacy, high recurrence rates, significant adverse reactions, and narrow therapeutic windows.6–9 These limitations","cbCairQBofFsoquB","https://ap.wps.com/l/cbCairQBofFsoquB","pdf",6169335,25,"English","# Abstract\n# Introduction\n## Rationale and clinical burden of breast cancer\n## Limitations of current therapies\n## Nanoparticle-based targeted delivery strategies\n## Active targeting concepts\n## Passive targeting via enhanced permeability and retention (EPR)","[{\"question\":\"Why are nanotechnology-based carriers considered for breast cancer therapy?\",\"answer\":\"They operate at the nanoscale, support diverse carrier designs, enable hydrophobic drug delivery, and allow controlled and targeted administration. Nanoparticles can be engineered for active or passive targeting and may provide synergistic effects.\"},{\"question\":\"What limits the effectiveness of many conventional nanoparticles in breast cancer?\",\"answer\":\"The immune system can detect and remove nanoparticles from the body, which restricts circulation time and reduces therapeutic efficacy.\"},{\"question\":\"How do cell membrane-derived nanoparticle systems improve tumor targeting?\",\"answer\":\"Cell membranes disguise nanoparticles in the bloodstream, enhance retention time in vivo, and leverage membrane-derived targeting properties to recognize breast cancer tumors and associated biomarkers. This approach has been explored for diagnostics, photothermal therapy, and vaccine development.\"}]","Advancements in Cell Membrane-Derived Biomimetic Nanotherapeutics for Breast Cancer - review | PDF",1790199256,63]